Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1111/jne.13309 | European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for colorectal neuroendocrine tumours |
| https://doi.org/10.1007/s12020-017-1273-x | Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms |
| https://doi.org/10.18632/oncotarget.24524 | Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms |
| https://doi.org/10.1053/j.semnuclmed.2012.01.002 | Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms |
| https://doi.org/10.1007/s00259-019-04501-6 | Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors |
| https://doi.org/10.2967/jnumed.120.258889 | First-in-Humans Study of the SSTR Antagonist 177Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy |
| https://doi.org/10.1159/000444803 | Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases |
| https://doi.org/10.2967/jnumed.120.258376 | First-in-Humans Application of 161Tb: A Feasibility Study Using 161Tb-DOTATOC |
| https://doi.org/10.1159/000494355 | Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study |
| https://doi.org/10.1016/j.ejca.2016.01.009 | Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up |
| https://doi.org/10.1039/c7dt01936j | Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152 Tb-DOTATOC |
| https://doi.org/10.1186/s12885-019-6000-y | Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival |
| https://doi.org/10.2967/jnumed.117.206631 | SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework |
| https://doi.org/10.1186/s13550-019-0538-1 | Preclinical investigations and first-in-human application of 152Tb-PSMA-617 for PET/CT imaging of prostate cancer |
| https://doi.org/10.2967/jnumed.119.241414 | Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy |
| https://doi.org/10.3390/cancers13071523 | Feasibility and Early Clinical Experience of Online Adaptive MR-Guided Radiotherapy of Liver Tumors |
| https://doi.org/10.1016/s1470-2045(22)00750-1 | Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study |
| https://doi.org/10.1056/nejmoa2504964 | Belzutifan for Advanced Pheochromocytoma or Paraganglioma |
| https://doi.org/10.1007/s00259-023-06245-w | Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors |
| https://doi.org/10.7150/thno.7851 | PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms |
| https://doi.org/10.1159/000489902 | Prognostic Evaluations Tailored to Specific Gastric Neuroendocrine Neoplasms: Analysis Of 200 Cases with Extended Follow-Up |
| https://doi.org/10.7150/thno.30357 | The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? |
| https://doi.org/10.1007/978-3-642-27994-2_30 | The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC |
| https://doi.org/10.1053/j.semnuclmed.2016.01.010 | Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues |
| Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. | |
| https://doi.org/10.1089/cbr.2016.2173 | First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44 Sc-DOTATOC: A Proof-of-Concept Study |
| https://doi.org/10.1111/ajco.12438 | Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long‐term outcomes |
| https://doi.org/10.1007/978-3-642-27994-2_20 | Rare Metastases Detected by 68Ga-Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors |
| https://doi.org/10.1007/s12149-018-1291-7 | Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications |
| https://doi.org/10.1097/md.0000000000002156 | Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems |
| https://doi.org/10.1007/978-3-642-27994-2 | Theranostics, Gallium-68, and Other Radionuclides |
| https://doi.org/10.1007/s00259-020-05127-9 | Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival |
| https://doi.org/10.3390/diagnostics11040605 | CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas |
| https://doi.org/10.1210/jc.2019-01204 | Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma |
| https://doi.org/10.2967/jnumed.119.237990 | Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma |
| https://doi.org/10.1016/j.bpg.2013.01.001 | Biotherapies for GEP-NETs |
| https://doi.org/10.2967/jnumed.121.263177 | Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy |
| https://doi.org/10.1111/jne.13100 | ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology |
| https://doi.org/10.1111/jne.13105 | ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors |
| https://doi.org/10.3390/diagnostics11020334 | Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors |
| https://doi.org/10.1016/j.cpet.2013.08.016 | Theranostics with Ga-68 Somatostatin Receptor PET/CT |
| https://doi.org/10.1097/md.0000000000001748 | Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme |
| https://doi.org/10.1007/s11154-017-9428-x | Cyto-histology in NET: what is necessary today and what is the future? |
| https://doi.org/10.3390/cancers13020358 | Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials |
| https://doi.org/10.1186/s40644-023-00556-9 | Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs |
| https://doi.org/10.3390/jpm14060654 | The Long Journey towards Personalized Targeted Therapy in Poorly Differentiated Thyroid Carcinoma (PDTC): A Case Report and Systematic Review |
| https://doi.org/10.2967/jnumed.124.268621 | PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy |
| https://doi.org/10.1002/pbc.31420 | Pediatric Neuroendocrine Tumors in Denmark: Incidence, Management, and Outcome From 1995 to 2020 |
| https://doi.org/10.1159/000545073 | Upregulation of SSTR2 Expression and Radioligand Binding of [18F]SiTATE in Neuroendocrine Tumour Cells with Combined Inhibition of Class I HDACs and LSD1 |
| https://doi.org/10.2967/jnumed.124.268288 | [18F]FDG and [68Ga]Ga-FAPI-04–Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms |
| https://doi.org/10.1007/s11102-024-01479-9 | IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly |
| https://doi.org/10.1186/s13075-026-03747-4 | Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis |
| https://doi.org/10.2967/jnumed.118.223537 | Novel Structured Reporting Systems for Theranostic Radiotracers |
| https://doi.org/10.1007/978-3-642-27994-2_32 | Peptide Receptor Radionuclide Therapy with 177Lu Labeled Somatostatin Analogs DOTATATE and DOTATOC: Contrasting Renal Dosimetry in the Same Patient |
| https://doi.org/10.1038/s41598-020-80855-4 | Impact of PET data driven respiratory motion correction and BSREM reconstruction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS) |
| https://doi.org/10.1007/s12020-020-02464-5 | Risk factors for pancreas and lung neuroendocrine neoplasms: a case–control study |
| https://doi.org/10.1097/mnm.0b013e328362cca6 | Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours |
| Pancreatic neuroendocrine neoplasms. | |
| https://doi.org/10.1097/rlu.0000000000004674 | Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors |
| https://doi.org/10.1007/s00330-023-09518-y | Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients |
| https://doi.org/10.1097/rlu.0000000000004629 | Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy |
| https://doi.org/10.1186/s40644-023-00614-2 | Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors |
| https://doi.org/10.1007/s11307-024-01899-w | Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas |
| https://doi.org/10.3389/fendo.2023.1285529 | Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3 |
| https://doi.org/10.1111/jne.13468 | Screening and surveillance practices for Multiple Endocrine Neoplasia type 1‐related Neuroendocrine Tumours in European Neuroendocrine Tumor Society Centers of Excellence ( ENETS CoE )—An ENETS MEN1 task force questionnaire study |
| https://doi.org/10.1007/s11523-025-01152-6 | Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board |
| https://doi.org/10.7150/thno.112588 | Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy |
| https://doi.org/10.1186/s13550-025-01305-8 | Predictors of renal function decline in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy |
| https://doi.org/10.1210/jc.2014-3640 | Comparison of the Utility of Cocaine- and Amphetamine-Regulated Transcript (CART), Chromogranin A, and Chromogranin B in Neuroendocrine Tumor Diagnosis and Assessment of Disease Progression |
| https://doi.org/10.1016/j.cpet.2016.12.001 | Imaging of Prostate Cancer Using 64 Cu-Labeled Prostate-Specific Membrane Antigen Ligand |
| https://doi.org/10.3390/jcm8081224 | Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms |
| https://doi.org/10.1055/s-0038-1636560 | Somatostatinrezeptor-PET/CT |
| https://doi.org/10.1007/978-3-642-27994-2_19 | High Uptake of 68Ga-DOTATOC in Spleen as Compared to Splenosis: Measurement by PET/CT |
| https://doi.org/10.1007/s00292-013-1888-5 | Neuroendokrine Neoplasien des distalen Jejunums und Ileums |
| https://doi.org/10.1053/j.semnuclmed.2016.06.001 | Advances in the Diagnosis of Neuroendocrine Neoplasms |
| https://doi.org/10.1097/md.0000000000006062 | The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy |
| https://doi.org/10.1097/rlu.0000000000002788 | Metastatic Nasopharyngeal Carcinoma Treated With Intraarterial Combined With Intravenous Peptide Receptor Radionuclide Therapy |
| https://doi.org/10.1111/ajco.13671 | Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region |
| https://doi.org/10.1007/s00330-024-10788-3 | Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [18F]SiTATE |
| https://doi.org/10.1159/000518895 | Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours |
| https://doi.org/10.1097/rlu.0000000000004621 | Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine Tumor |
| https://doi.org/10.3389/fonc.2023.1194152 | Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT |
| https://doi.org/10.3389/fonc.2024.1352538 | Synchronous neuroendocine liver metastases in comparison to primary pancreatic neuroendocrine tumors on MRI and SSR-PET/CT |
| https://doi.org/10.1136/jcp-2024-209658 | S100 protein is commonly expressed in neuroendocrine tumours of major and minor ampulla |
| https://doi.org/10.7150/thno.102910 | C-X-C motif chemokine receptor 4-directed PET signal in the arterial tree is not consistently linked to calcified plaque burden and cardiovascular risk |
| https://doi.org/10.1530/eo-25-0041 | Paltusotine versus octreotide: different effects on radioligand uptake in neuroendocrine tumours |
| https://doi.org/10.2967/jnumed.125.270755 | Diagnostic Performance of [ 18 F]PSMA-1007 PET/CT on Proven PSMA-Positive Hepatocellular Carcinoma: A Prospective Clinical Study |
| https://doi.org/10.1007/s11307-018-1293-9 | Impact of Tumor Burden on Quantitative [68Ga] DOTATOC Biodistribution |
| https://doi.org/10.12968/bjon.2016.25.4.s12 | Gastroenteropancreatic neuroendocrine tumours: an overview |
| https://doi.org/10.1016/j.athoracsur.2014.04.020 | Postsurgical Follow-Up Is Always Necessary in Bronchial Carcinoid |
| https://doi.org/10.1007/s12020-021-02639-8 | Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms |
| https://doi.org/10.1007/s00761-011-2052-6 | Neuroendokrine Neoplasien des gastroenteropankreatischen Systems |
| https://doi.org/10.1007/s12020-018-1592-6 | A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms |
| https://doi.org/10.1016/j.cgh.2023.10.033 | Expanding Role of Gastroenterology in the Staging of Digestive Neuroendocrine Tumors: Updates From the American Joint Committee on Cancer Version 9 Cancer Staging System |
| https://doi.org/10.1007/s13304-021-01123-2 | Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis |
| https://doi.org/10.1097/mpa.0000000000002425 | Somatostatin Analogs Versus Active Surveillance in Small Pancreatic Neuroendocrine Tumors |
| https://doi.org/10.1016/j.jpedsurg.2025.162506 | Surgical Management of Paediatric Appendiceal Neuroendocrine Tumors: A 26-Year Danish Nationwide Retrospective Cohort Study |
| https://doi.org/10.1007/s11377-020-00428-9 | Neuroendokrine Neoplasien des Gastrointestinaltrakts |
| https://doi.org/10.1186/s41824-025-00273-5 | Feasibility of different lymph node metastases delineation approaches in [18F]SiTATE PET/CT imaging in NET patients |
| https://doi.org/10.1530/ec-25-0709 | Digital vs conventional glycemic monitoring in rare endocrine cancers: comparison of effectiveness during chemotherapy |